Enhertu (fam-trastuzumab deruxtecan-nxki) - Daiichi Sankyo, AstraZeneca
DS-8201: Data presentation from P2 DESTINY-Breast01 trial (NCT03248492) for (HER2)-positive breast cancer at ASCO (May 29- June 02, 2020) (Daiichi Sankyo) - Dec 18, 2019 - Data presentation from P2 DESTINY-Gastric01 trial (NCT03329690) for HER2-overexpressing advanced gastric cancer at ASCO (May 29- June 02, 2020) 
P2 data
https://www.daiichisankyo.com/media_investors/investor_relations/ir_calendar/files/005462/R&D%20Day%202019_E.pdf
 
Dec 18, 2019
 
 
d229efc2-86ad-42f0-9d02-c7d6ccd2eec3.jpg